Dr Srour on the Mechanism of Action of ALLO-316 in Metastatic Clear Cell RCC
May 22nd 2023
Samer A. Srour, MB ChB, MS, discusses the mechanism of action of ALLO-316, which is being investigated for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma, and details safety findings from the phase 1 TRAVERSE study evaluating ALLO-316 in this patient population.